Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Brain Neoplasms 6Prostatic Neoplasms 2Cognitive Dysfunction 2Breast Neoplasms 2Tobacco Use Disorder 1Recurrence 1Rectal Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Motor Activity 1Lung Neoplasms 1Glioblastoma 1Ependymoma 1Craniopharyngioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1

Interventions

Memantine 2lithium sulfate 1lime 1fasudil 1XENP 1595 1Ramipril 1Methylphenidate 1Lithium 1Infliximab 1Ibuprofen 1Exercise 1Cannabidiol 1Behavior Therapy 1Aspirin 1Ashwagandha 1Anticonvulsants 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Cognitive Dysfunction × Memantine × Clear all
NCT06727773 2026-05-06

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
90 enrolled
Breast

Breast Neoplasms, Motor Activity, Cognitive Dysfunction

NCT04033419 2023-04-20

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
55 enrolled 21 charts

Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡